World Anti-Obesity Drugs Market

World Anti-Obesity Drugs Market

This report analyzes the worldwide markets for Anti-Obesity Drugs in Millions of US$. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2005 through 2015. The report profiles 85 companies including many key and niche players worldwide such as Abbott Laboratories, Alizyme Plc, Amylin Pharmaceuticals, Inc., AstraZeneca Plc., F.HOFFMANN-LA ROCHE LTD., GlaxoSmithKline Plc, Sanofi-Aventis SA, SuperGen, Inc., Takeda Pharmaceutical Company Limited, and VIVUS, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

ANTI-OBESITY DRUGS
A GLOBAL STRATEGIC BUSINESS REPORT MCP-1722


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3


II. EXECUTIVE SUMMARY

1. Industry Overview II-1
Current & Future Analysis II-1
Factors Influencing the Market II-1
Obesity - A Global Epidemic II-1
Table 1: Global Overweight Prevalence (2006): Overweight
Population (%) of Select Countries (includes corresponding
Graph/Chart) II-3

Table 2: Abdominal Obesity Prevalence (%) by Region and Sex
(includes corresponding Graph/Chart) II-3
Trends and Issues II-4
Obesity: An Unmet Medical Need II-4
Rising Demand for Obesity Therapeutics II-4
Barriers to Development of Effective Drugs II-4
New Research Aids in Discovery of Novel Drugs II-5
Growing Problem of Obesity in Asia Particularly China II-5

2. Competition II-6
Roche Leads the Race II-6
Table 3: Leading Brands in the Global Anti-obesity Drugs
Market (2007): Percentage Share Breakdown of Revenues for
Xenical/orlistat, Reductil/Meridia (sibutramine), Alli,
Acomplia and Others (includes corresponding Graph/Chart) II-6
Competition Grows with Pipeline Drugs II-7
Current Anti-Obesity Drugs in Pipeline: 2008 II-7

3. Obesity - An Introduction II-8
Diagnosis of Obesity II-8
BMI Calculation and Classification II-8
Waist Circumference and BMI II-9
Causes of Obesity II-9
Unhealthy Eating Habits II-9
Environmental and Genetic Factors II-9
Sedentary Lifestyle II-9
Alcohol Intake II-9
Childhood Obesity II-10
Psychological Factors II-10
Pregnancy II-10
Hormonal Disorders II-10
Drugs II-10
Aging II-10
Risks Associated with Obesity II-10

4. Obesity Treatment II-12
Dietary Therapy II-12
Exercise Therapy II-12
Behavior Therapy II-12
Pharmacotherapy II-12
Weight Loss Surgery II-12
Invasive Vis-à-vis Non-invasive Procedures II-12
A Brief Review of Select Invasive Procedures II-13
Bariatric Surgery II-13
Laparoscopic Adjustable Gastric Banding II-13
Vertical Banded Gastroplasty (VBG) II-13
Roux-en-Y Gastric Bypass Procedure (RYGB) II-13
Lap-Band Procedure II-13
Gastric Band Procedure II-13
Gastric Bypass Procedure II-13
Doudenal Switch II-13
Prescription Drugs Vis-à-vis Non-Prescription Drugs II-14
Table 4: Obesity Treatment Options and Corresponding Success
Rate II-14

5. Anti-Obesity Drugs- An Insight II-15
Introduction II-15
Mechanism of Action II-15
Review of Available Drugs II-16
Phentermine II-16
Sibutramine II-16
Orlistat II-16
Anti-obesity Drugs, Brands and Mechanism of Action II-17
Table 5: Global Anti-obesity Prescription Drugs Market
(2006): Percentage Share Breakdown of Prescriptions by
Physician Practices - Primary Care Physicians (PCP),
Internal Medicine, Obsterics/Gynecology,
Endocrinology/Diabetes, Psychiatry/Neurology, Cardiology and
Others (includes corresponding Graph/Chart) II-17
Review of Select Drugs Awaiting approval / Under Trials II-17

6. Recent Clinical Trials II-20
Genaera Initiates First Human Trial of Trodusquemine II-20
Neurogen Completes First Trial of NGD-4715 II-20
Alizyme Secures USFDA Approval for Cetilistat Trials II-20
GW Pharma to Start Human Trials of New Anti Obesity Drug II-20
Epix Completes Phase Ib Trial of PRX - 07034 II-20
7TM Pharma Starts Phase I/II Trial of TM30339 II-21
Arena Starts Phase III Clinical Trials of Lorcaserin II-21
Drug Induced Serotonin Could Promote Weight Loss II-21
Takeda Initiates Phase II Clinical Trials of ALT-962 II-21
Glenmark to Commence Phase I Trial of New Anti-Obesity Drug II-21
Amylin-Leptin Integrated Therapy to Treat Obesity II-21
Vivus Completes Phase II Trial of Qnexa II-22
VERNALIS Starts Phase I trial for Obesity II-22
7TM Pharma Completes Phase I/ II Clinical Trials of TM30338 II-22
Manhattan Pharmaceuticals Starts Phase I trial of Oleoyl estrone II-22
Arena Completes Phase2b Trials of APD356 II-23
Metabolic Accomplishes Phase 2b Trials of AOD9604 II-23

7. Product Approvals/Launches II-24
Sanofi-Aventis Receives Swiss Approval for Acomplia II-24
Zydus Cadila Introduces Slimona II-24
Torrent Introduces Rimoslim II-24
Gencor Introduces Slimaluma II-24
Orexigen Develops Excalia II-24
Scripps Research Institute Develops Vaccine for Obesity II-25
Sanofi-Aventis Receives Approval to Market Obesity Drug in EU II-25
Sanofi-Aventis Rolls Out Acomplia II-25
Sanofi Secures Approval for Acomplia in the UK II-25
Novo Nordisk to Develop Anti-obesity Drug II-25
Sanofi-Aventis Receives Approval to Market Acomplia in Mexico II-26
Ind-Swift Introduces Sibuslim-10 II-26
Wellnx Launches NV II-26
Iron-Tek Introduces Appetite Suppressant II-26
Yamanouchi and Keio University Discover Target Molecule for
Developing Anti-obesity Drug II-26

8. Recent Industry Activity II-27
Pfizer Halts CP-945, 598 Development II-27
Shionogi to Acquire Sciele Pharma II-27
Anthill Inks Agreement with Zafgen II-27
EMEA Suspends Acomplia II-27
GlaxoSmithKline to Sell Alli as OTC Drug II-27
Sanofi-Aventis to Market Acomplia in UK II-27
Orexigen Receives 4th US Patent for Contrave II-28
BELLUS Health to Acquire Innodia II-28
Ore Secures License to Develop Romazarit II-28
GlaxoSmithKline Receives FDA Approval for Orlistat II-28
Pfizer Receives Approval for Slentrol II-28
GlaxoSmithKline Secures Licensing Rights of Orlistat II-28
Pfizer Collaborates with Bristol-Myers Squibb II-29
Takeda Collaborates with LG Life Sciences II-29
Takeda to Acquire Paradigm II-29
Sanofi-Aventis Secures Reimbursement Status for Acomplia II-30
AstraZeneca Inks Agreement with Palatin Technologies II-30
Switzerland Includes Acomplia in Reimbursement List II-30
Allergan Pockets EndoArt II-30
Sanofi-Aventis Receives Approval for Acomplia in Brazil II-31
Biocon Inks MoU with Neopharma II-31
Aurigene Partners with Forest Laboratories II-31
Pfizer Licenses Obesity Compounds from Bayer Pharmaceuticals II-31
Merck Terminates Collaboration with Nastech II-32
Sanofi-Aventis to Receive Rights for Rimonabant II-32
UMN Pharma Inks Agreement with Crucell and DSM Biologics II-32
7TM Pharma Pockets CareX SA II-32
BioLineRx Inks Licensing Agreement with Yissum II-33
Aegis Inks Licensing Agreement with Albany Medical College II-33
Manhattan’s Obesity Drug Approved for Human Trials II-33
Chugai Halts Development of Anti-Obesity Agent II-33
HSG Acquires Polymann II-33
Orchid Pockets Bexel II-34

9. Focus on Select Players II-35
Abbott Laboratories (US) II-35
Alizyme Plc (UK) II-35
Amylin Pharmaceuticals, Inc. (US) II-35
AstraZeneca Plc (UK) II-36
F. HOFFMANN-LA ROCHE LTD. (Switzerland) II-36
GlaxoSmithKline Plc (UK) II-36
Sanofi-Aventis SA (France) II-37
SuperGen, Inc. (USA) II-37
Takeda Pharmaceutical Company Limited (Japan) II-38
VIVUS, Inc. (US) II-38

10. Global Market Perspective II-39
Table 6: World Recent Past, Current & Future Market Analysis
for Anti-Obesity Drugs by Geographic Region - US, Europe and
Rest of World Independently Analyzed with Annual Sales Figures
in US$ million for Years 2005 through 2015 (includes
corresponding Graph/Chart) II-39

Table 7: World 10-Year Perspective for Anti-Obesity Drugs by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Europe and Rest of World Markets for Years 2006, 2009 and
2015 (includes corresponding Graph/Chart) II-40


III. MARKET

1. The United States III-1
A.Market Analysis III-1
Market Overview III-1
Table 8: Leading Product Segments in the US Weight Loss
Market (2008E): Percent Share Breakdown of Revenues for
Diet Drinks, Health Clubs, Bariatric Surgery, Diet Foods,
Artificial Sweeteners, Weight Loss Centers, Medically
Supervised Programs, Meal Replacements & Appetite
Suppressants, Prescription Drugs, Low Calorie Diet Programs
and Others (includes corresponding Graph/Chart) III-1
Obesity Catching Them Young III-2
New Drugs to Rule the Market III-2
37 States Experience Increase in Adult Obesity Rate III-2
Statistical Data III-3
Table 9: US Obesity Rate (2007): Prevalence Rate of Leading
States III-3
Table 10: US Obesity Prevalence Estimates and Forecasts
(2006-2020) (includes corresponding Graph/Chart) III-4
Table 11: US Overweight Prevalence (1998 & 2002): Breakdown
of Adult population by Category - Overweight and Obese III-4

Table 12: US Obesity Prevalence (2005-2006): Breakdown of
Population (%) by Sex and Age Group (includes corresponding
Graph/Chart) III-4

Table 13: US Anti-obesity Drugs Market (2006 & 2007):
Number of Obese People Treated in Million III-5
Reimbursement Scenario III-5
Regulatory Environment III-5
Insufficient Regulatory and Enforcement Laws III-5
Obesity and Related Ailments: Burden on Societal and
Economic Cost III-5
Competition III-6
Table 14: US Anti-obesity Drugs Market (2006 and 2007):
Percentage Share Breakdown of Revenues by Brand - Meridia,
Xenical and Others (includes corresponding Graph/Chart) III-6
Recent Clinical Trials III-6
Product Approval/Launches III-8
Strategic Corporate Developments III-9
Review of Major Players III-12
B.Market Analytics III-14
Table 15: US Recent Past, Current & Future Analysis for
Anti-Obesity Drugs Market Independently Analyzed with Annual
Sales Figures in US$ million for Years 2005 through 2015
(includes corresponding Graph/Chart) III-14

2. Europe III-15
A.Market Analysis III-15
Market Overview III-15
Lack of Reimbursement: Barrier to Market Growth III-15
Statistical Data III-16
Table 16: Obesity Prevalence (2007) in Select European
Union Countries: Obesity Rates by Gender (includes
corresponding Graph/Chart) III-16
Table 17: Europe Obesity Prevalence (2007) by Gender and
Age Category (in 000s) (includes corresponding Graph/
Chart) III-16
Overview of Novel Policies Adopted by Select European
Countries to Prevent Obesity III-17
B.Market Analytics III-18
Table 18: European Recent Past, Current & Future Analysis
for Anti-Obesity Drugs by Geographic Region/Country -
France, Germany, Italy, UK and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2005 through 2015 (includes corresponding
Graph/Chart) III-18

Table 19: European 10-Year Perspective for Anti-Obesity
Drugs by Geographic Region/Country - Percentage Breakdown of
Dollar Sales for France, Germany, Italy, UK and Rest of
Europe Markets for Years 2006, 2009 and 2015 (includes
corresponding Graph/Chart) III-19

2a. France III-20
A.Market Analysis III-20
Market Overview III-20
Changing Lifestyle Alter Health Profile III-20
Product Approval/Launches III-20
Strategic Corporate Developments III-20
Sanofi-Aventis SA - A Key Player III-21
B.Market Analytics III-22
Table 20: French Recent Past, Current & Future Analysis for
Anti-Obesity Drugs Market Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2005 through 2015
(includes corresponding Graph/Chart) III-22

2b. Germany III-23
A.Market Analysis III-23
Table 21: German Anti-obesity Drugs Market (2005 and 2006):
Percentage Share Breakdown of Volume Sales by Leading Brands
- Meridia and Xenical and Others III-23
B.Market Analytics III-23
Table 22: German Recent Past, Current & Future Analysis for
Anti-Obesity Drugs Market Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2005 through 2015
(includes corresponding Graph/Chart) III-23

2c. Italy III-24
Market Analysis III-24
Table 23: Italian Recent Past, Current & Future Analysis for
Anti-Obesity Drugs Market Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2005 through 2015
(includes corresponding Graph/Chart) III-24

2d. The United Kingdom III-25
A.Market Analysis III-25
Market Overview III-25
Table 24: UK Childhood Prevalence (1995-2005): Percentage
of Obese Children Aged 2-15 years (includes corresponding
Graph/Chart) III-25
Recent Clinical Trials III-26
Product Approval/Launches III-26
Strategic Corporate Developments III-27
Review of Major Players III-27
B.Market Analytics III-29
Table 25: UK Recent Past, Current & Future Analysis for
Anti-Obesity Drugs Market Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2005 through 2015
(includes corresponding Graph/Chart) III-29

2e. Rest of Europe III-30
A.Market Analysis III-30
Recent Clinical Trials III-30
Product Approval/Launches III-30
Strategic Corporate Developments III-31
F. HOFFMANN-LA ROCHE LTD. - A Key Player III-31
B.Market Analytics III-32
Table 26: Rest of Europe Recent Past, Current & Future
Analysis for Anti-Obesity Drugs Market Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2005 through 2015 (includes corresponding Graph/Chart) III-32

3. Rest of World III-33
A.Market Analysis III-33
Brief Review of Select Regions III-33
Canada III-33
Table 27: Canadian Obesity Prevalence (1979 & 2004):
Obesity Rate by Age Group (includes corresponding
Graph/Chart) III-33

Table 28: Canadian Adult Overweight and Obesity Prevalence
(2004): Breakdown of Population (in 000s) by Sex III-33
Asia-Pacific III-34
Australia III-34
Table 29: Prevalence Rate (%) of overweight/obese
Students in Australia (includes corresponding Graph/
Chart) III-34
China III-35
India III-35
Drugs Under Development by Indian Companies III-35
Japan III-35
Takeda Pharmaceutical Company Limited - A Key Player III-35
Korea III-36
Use of Diet Pills Lack Proper Monitoring III-36
New Zealand III-36
Recent Clinical Trials III-36
Product Approval/Launches III-37
Strategic Corporate Developments III-38
B.Market Analytics III-41
Table 30: Rest of World Recent Past, Current & Future
Analysis for Anti-Obesity Drugs Market Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2005 through 2015 (includes corresponding Graph/Chart) III-41


IV. COMPETITIVE LANDSCAPE